Search results
How Much Will Pfizer Pay Out in Dividends This Year? | The Motley Fool
The Motley Fool· 44 minutes agoA vaccine and an antiviral treatment for COVID-19 made Pfizer (PFE 0.66%) a household name in recent years, but this isn't all the company sells. There ...
Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine
Barrons.com· 4 days ago“We continue to have active conversations with both manufacturers, and the negotiations are...
Pfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
Reuters via Yahoo Finance· 4 days agoInvestors have fled from Pfizer as pandemic worries declined and billions of dollars in COVID-19 ...
Vaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines By Investing.com
Investing.com· 3 days agoVaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindles
Quartz· 4 days agoPharma giant Pfizer announced Wednesday another cost-cutting initiative as the company struggles...
Equities Analysts Issue Forecasts for Pfizer Inc.’s Q3 2025 Earnings (NYSE:PFE)
ETF DAILY NEWS· 1 day agoPfizer Inc. (NYSE:PFE – Free Report) – Stock analysts at Zacks Research dropped their Q3 2025 EPS estimates for Pfizer in a research report issued on Wednesday ...
Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027 - Pfizer (NYSE:PFE)
Benzinga· 3 days agoPfizer Inc. PFE has launched a multi-year cost-cutting initiative aimed at saving approximately $1.5...
Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts
CNBC· 4 days agoPfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to...
Arizona researcher publishes study on COVID-19 vaccine and tinnitus
ABC 15 Phoenix· 1 day agoA newly published scientific study about the COVID-19 vaccine found people with certain preexisting medical conditions were more likely to report ringing in the ears after ...
Better Buy: Inovio Pharmaceuticals vs. Novavax
The Motley Fool via AOL· 4 days agoThe COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to...